ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains (PDT/PDL)

This study is enrolling participants by invitation only.

Sponsors and Collaborators: University of California, Irvine
Beckman Laser Institute Medical Clinic
QLT Inc
Information provided by: University of California, Irvine
ClinicalTrials.gov Identifier: NCT00556946
  Purpose

This research study designed to determine the effect on port wine stains (PWS) of liposomal BPD-MA termed verteporfin (distributed for medical indications asVisudyne by QLT, Inc., Vancouver, Canada) by intravenous (IV) infusion for photodynamic therapy (PDT) or combined PDT and pulsed dye laser (PDL) therapy (PDT + PDL). The standard treatment for PWS is PDL alone. This lightens some PWS but many lesions are not completely removed.

PDT uses a medication and light together to cause injury to a target. The medication is given and then light is directed at the desired area of treatment to achieve an effect. PDT has been used to treat some skin conditions including pre-cancers and skin cancers. Using PDT or PDT immediately followed by PDL therapy may improve PWS lightening. At this time, both PDT and PDT + PDL therapy for treatment of PWS is investigational. The type and amount of medication and light which may be used to treat PWS is not known, and is likely to be different than those used for other PDT treatments.


Condition Intervention Phase
Port Wine Stains
Procedure: Combine photodynamic therapy and Pulsed Dye Laser
Phase I

Genetics Home Reference related topics:   Skin Conditions  

MedlinePlus related topics:   Birth Defects   Skin Conditions  

ChemIDplus related topics:   Verteporfin  

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Official Title:   Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains

Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • Combined sub-threshold photodynamic and pulsed dye laser therapy can be used to safely achieve improved PWS lesion lightening as compared to either sub-threshold photodynamic therapy or pulsed dye laser therapy alone. [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]

Estimated Enrollment:   30
Study Start Date:   August 2005
Estimated Study Completion Date:   July 2012
Estimated Primary Completion Date:   July 2012 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
2: Experimental
Four circular test sites with a 2 cm diameter will be delineated using a yellow high lighter marker. The first test site will be a control and receive no treatment. The second test site will be treated with the pulsed dye laser at standard parameters.
Procedure: Combine photodynamic therapy and Pulsed Dye Laser
Verteporfin IV for phototherapy

Detailed Description:

Procedures will be performed at the Surgery Laser Clinic at the Beckman Laser Institute at the University of California Irvine.

At an initial visit, a brief history and physical will be performed.

The history will include: 1) previous treatment to my PWS; 2) current medications; 3) history of light sensitivity; 4) risk of pregnancy and use of birth control if a female of child-bearing age.

The physical will include: 1) measurement and evaluation of PWS; 2) measurement of blood pressure, blood cell count, general chemistries (including liver function tests) and ANA, which might indicate an increased sensitivity to light.

On the day of treatment, the same brief physical and history will be repeated. A urine pregnancy test will be performed if a female of childbearing age.

Four circular test sites of PWS will be selected. One test site will receive no treatment. The second test sites will be treated with the pulsed dye laser at standard setting and protective eyeglasses to shield the eyes during the laser treatment.

For two additional test spots, the photodynamic therapy (PDT)verteporfin by intravenous over a 10-minute period. After receiving the verteporfin, the skin and eyes will be sensitive to light for the next 5 days. The light sensitive protection precautions will be instructed.

optical Doppler tomography unit(ODT) measurements, similar to shining a flash light to PWS and measuring the light response,which provide information about how blood is flowing through the PWS.

Photographs and light measurements will be taken follow-up visits at 1 day, 3 days, 1, 2, 4, 8 and 12 weeks after the study treatment, at these visits blood may also be drawn at these follow-up visits to check for blood substances that promote blood vessel formation.

At the end of the study, blood tests will be drawn to assess cell count and general chemistries.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Adult 18 years and older
  • Have a PWS on an area other than the face
  • a negative pregnancy test and non pregnant or nursing

Exclusion Criteria:

  • under 18 years of age
  • have an allergy to verteporfin, porfimer sodium or other porphyrins
  • have a history of porphyria (a disease that can cause sensitivity to light)
  • have had treatment to the PWS test sites in the last 8 weeks
  • have an active uncontrolled infection or other significant disease
  • currently using medications that will make sensitive to light such as tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics and griseofulvin
  • currently using medications that increase bleeding including aspirin, coumadin or non-steroidal anti-inflammatory drugs.
  • have very dark skin which sensitive to laser treatment
  • have a positive ANA (lab tests which indicates sensitive to light)
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00556946

Locations
United States, California
Beckman Laser Medical Clinic,University    
      Irvine, California, United States, 02612

Sponsors and Collaborators
University of California, Irvine
Beckman Laser Institute Medical Clinic
QLT Inc

Investigators
Principal Investigator:     Kristen Kelly, M.D     Beckman Laser Institute Medical Clinic    
  More Information

Responsible Party:   Beckman Laser Institute ( Kristen Kelly,M.D )
Study ID Numbers:   AR-51443; PHS-NIH, P41-RR01192;NIH-LAMMP
First Received:   November 9, 2007
Last Updated:   December 19, 2007
ClinicalTrials.gov Identifier:   NCT00556946
Health Authority:   United States: Institutional Review Board

Keywords provided by University of California, Irvine:
Vascular Malformation  

Study placed in the following topic categories:
Skin Diseases
Nevi flammei, familial multiple
Port-Wine Stain
Vascular Malformations
Verteporfin
Connective Tissue Diseases
Skin Abnormalities
Infant, Newborn, Diseases
Congenital Abnormalities

Additional relevant MeSH terms:
Skin and Connective Tissue Diseases
Congenital, Hereditary, and Neonatal Diseases and Abnormalities

ClinicalTrials.gov processed this record on May 15, 2008